BIOMAT Database Logo BIOMAT Database Logo

Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. 1986

E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of carboplatin (400 mg/m2) given as an iv bolus every 4 weeks in patients with measurable advanced ovarian cancer who had failed or relapsed following standard platinum-containing therapy. Four complete and eight partial responses were seen in 43 evaluable patients. Toxicity was primarily hematologic. Myelosuppression, particularly thrombocytopenia, was severe in one-third of patients treated at the 400-mg/m2 starting dose. Carboplatin has antitumor activity in this clinical setting, but a lower starting dose is recommended.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006402 Hematologic Diseases Disorders of the blood and blood forming tissues. Blood Diseases,Hematological Diseases,Blood Disease,Disease, Blood,Disease, Hematologic,Disease, Hematological,Diseases, Blood,Diseases, Hematologic,Diseases, Hematological,Hematologic Disease,Hematological Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.
August 1986, Cancer treatment reports,
E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
June 1986, Cancer treatment reports,
E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Phase II study of 2'-deoxycoformycin in patients with renal cell carcinoma. A National Cancer Institute of Canada Clinical Trials Group study.
August 1991, Investigational new drugs,
E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
November 1986, Cancer treatment reports,
E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.
September 1988, Investigational new drugs,
E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
May 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.
June 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
February 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Phase II study of i.v. menogaril in patients with malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group Study.
January 1987, Cancer treatment reports,
E A Eisenhauer, and K D Swenerton, and J F Sturgeon, and S Fine, and S E O'Reilly
Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
April 1993, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!